Investigating the association between SARS-CoV-2 infection, COVID-19 vaccination, and autoimmune diseases in a pediatric population: a comprehensive analysis
- PMID: 40369546
- PMCID: PMC12080261
- DOI: 10.1186/s12969-025-01093-4
Investigating the association between SARS-CoV-2 infection, COVID-19 vaccination, and autoimmune diseases in a pediatric population: a comprehensive analysis
Abstract
Background: During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims to investigate the incidence of AIDs in children before and during the pandemic and explores potential links to SARS-CoV-2 vaccination.
Methods: We analyzed 493,705 anonymized medical records from Maccabi Healthcare Services, Israel's second-largest healthcare provider, to study AID incidence during 2014-2022. The study period was divided into three phases: two pre-pandemic phases of equal duration (A and B) and a pandemic phase (C).
Results: Of 4,596 (0.9%) patients diagnosed with an AID in the cohort, incidence rates were 0.9% for Group A (2014-2016), 1.0% for Group B (2017-2019), and 0.9% for Group C (2020-2022) (p = 0.13). Logistic regression showed no significant differences in overall autoimmune disease incidence between the pre-COVID and COVID periods. Notably, specific conditions like celiac disease showed reduced incidence in Group A (OR 0.8309, p = 0.0071) while arthritis was significantly more common in Groups A and B. Additionally, COVID-19 diagnosis was not significantly associated with increased autoimmune disease risk (HR 1.092, p = 0.491); however, receiving at least one COVID vaccine was linked to higher risk (HR 1.2323, p = 0.0033).
Conclusion: Our findings suggest that the overall incidence of new-onset autoimmune diseases in children remained relatively stable during the COVID-19 pandemic. The study indicates a potential association between COVID-19 vaccination and an increased risk of developing autoimmune diseases, necessitating further research to elucidate long-term effects in the pediatric population.
Keywords: Autoimmune diseases; COVID-19 infection; COVID1-19 vaccination; Epidemiology; Pediatric rheumatology.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
High incidence of multisystem inflammatory syndrome and other autoimmune diseases after SARS-CoV-2 infection compared to COVID-19 vaccination in children and adolescents in south central Europe.Clin Exp Rheumatol. 2023 May;41(5):1183-1191. doi: 10.55563/clinexprheumatol/i1l2xn. Epub 2022 Nov 12. Clin Exp Rheumatol. 2023. PMID: 36377567
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
Can we get out of the COVID pandemic without adequate vaccination coverage in the pediatric population?Ital J Pediatr. 2022 Aug 19;48(1):150. doi: 10.1186/s13052-022-01339-x. Ital J Pediatr. 2022. PMID: 35986340 Free PMC article.
-
Insights into new-onset autoimmune diseases after COVID-19 vaccination.Autoimmun Rev. 2023 Jul;22(7):103340. doi: 10.1016/j.autrev.2023.103340. Epub 2023 Apr 17. Autoimmun Rev. 2023. PMID: 37075917 Free PMC article. Review.
-
New-onset autoimmune phenomena post-COVID-19 vaccination.Immunology. 2022 Apr;165(4):386-401. doi: 10.1111/imm.13443. Epub 2022 Jan 7. Immunology. 2022. PMID: 34957554 Review.
References
-
- Hejrati A, Rafiei A, Soltanshahi M, Hosseinzadeh S, Dabiri M, Taghadosi M, et al. Innate immune response in systemic autoimmune diseases: a potential target of therapy. Inflammopharmacol. 2020;28(6):1421–38. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous